Format

Send to

Choose Destination
Expert Opin Drug Deliv. 2018 Feb;15(2):185-196. doi: 10.1080/17425247.2018.1378180. Epub 2017 Sep 12.

Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.

Author information

1
a Division of Radiotherapy and Imaging , The Institute of Cancer Research , London , UK.
2
b The Royal Marsden NHS Foundation Trust , Department of Nuclear Medicine , London , UK.

Abstract

INTRODUCTION:

Radioimmunotherapy (RIT) with monoclonal antibodies and their fragments labelled with radionuclides emitting α -particles, β-particles or Auger electrons have been used for many years in the development of anticancer strategies. While RIT has resulted in approved radiopharmaceuticals for the treatment of hematological malignancies, its use in solid tumors still remains challenging.

AREAS COVERED:

In this review, we discuss the exciting progress towards elucidating the potential of current and novel radioimmunoconjugates and address the challenges for translation into clinical practice.

EXPERT OPINION:

There are still technical and logistical challenges associated with the use of RIT in routine clinical practice, including development of novel and more specific targeting moieties, broader access α to α-emitters and better tailoring of pre-targeting approaches. Moreover, improved understanding of the heterogeneous nature of solid tumors and the critical role of tumor microenvironments will help to optimize clinical response to RIT by delivering sufficient radiation doses to even more radioresistant tumor cells.

KEYWORDS:

Radioimmotherapy; monoclonal antibody; radionuclide therapy; targeted radionuclide therapy

PMID:
28893110
DOI:
10.1080/17425247.2018.1378180
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center